The first public suggestion of a link between MMR vaccine and autism was made on a Danish television programme in 1993, by the mother of a child with autism. Although no epidemiological or biological evidence of a causal link was found in a subsequent investigation undertaken in 1994 by the Danish Department of Epidemiology at the National Statens Serum Institute, the hypothesis caught on, particularly among parents' groups. Lawyers became interested.
Vaccination and vaccine safety are issues of major concern to the public, their elected representatives and all health care workers. Possible adverse reactions to vaccines attract considerable attention from various pressure groups and from the media, with important and possibly catastrophic effects on public confidence in immunisations and on vaccine-uptake. In 1998, Wakefield and others published a case series of 12 children referred with bowel symptoms to a tertiary paediatric gastroenterology unit. 1 Nine of the children had autistic spectrum disorders including one with Asperger's syndrome, one had disintegrative psychosis, two had possible post viral/vaccinial encephalitis. In eight of the 12, the parents or the child's doctor associated the onset of the child's condition with the MMR vaccine, with a mean interval between vaccination and recalled onset of symptoms of 6.4 days, range 1-14. This paper and earlier work from the same group, suggesting an association between measles-containing vaccinations and inflammatory bowel disease 2 (work not confirmed in their subsequent studies 3, 4 ), received considerable media attention with an ongoing adverse effect on vaccination rates in the United Kingdom where overall MMR uptake has fallen from 92% in 1997 to 84% in 2001. Many children are now at risk of measles, mumps and rubella and the possibility of eradication of measles has been seriously delayed.
Since the first MMR vaccine is given around 12-15 months of age and the mean age at which parents of children with autism first report concern about their child's development is 18-19 months, a close temporal association in some autistic children would be expected by chance. In 1999, we published the results of a population-based epidemiological study which investigated the possible causal relationship between Correspondence: B Taylor, Centre for Community Child Health, Royal Free and University College Medical School, University College London Royal Free Campus, London NW3 2PF, UK. E-mail: b.taylor@rfc.ucl.ac.uk MMR vaccine and autism. 5 Four hundred and ninetyeight children with autism born since 1979 were identified from special needs/disability registers and special schools in eight health districts in North East London. Information from clinical records was linked to (independently recorded) immunisation data held on the regional child health computing system. No evidence of a change in trend in incidence or age at diagnosis associated with the introduction of MMR vaccination was found. The self-control case-series method was used to investigate possible clustering of onsets within defined post-vaccination periods up to 2 years, assessing age when the parents first became concerned about their child's development, age at diagnosis and, in the cases where it was a feature, age at regression of development or behaviour. No significant relationships were identified. A subsequent paper using the same dataset and markers of the onset of autism, demonstrated no effect at any time after MMR vaccination. 6 Other epidemiological studies have confirmed these negative findings. 7 The pattern of bowel abnormalities identified in the Wakefield et al 1 case series was described as a specific 'autistic enterocolitis'. The case for such an entity has not been proven and there are strong arguments 8 against the biological plausibility of the sequence suggested as leading to the onset of autism-whereby a previously normal child receives MMR vaccine, develops bowel problems ('autistic enterocolitis') which leads to abnormal absorption of dietary or digestive constituents and the child then undergoes developmental and/or behavioural regression ('regressive autism'). This 'new-variant' autism has been incriminated as the cause of the apparent increase in the prevalence of autistic spectrum disorders, although Fombonne 9 has presented evidence that the observed increase does not reflect a real rise.
Although the original paper 1 described a short interval between vaccination and symptoms, Wakefield has recently postulated 10 that the onset of MMR-induced 'regressive autism' may occur after a prolonged induction interval and requires in addition co-factors such as an intercurrent infection, the child receiving antibiotics, atopy in the child, a strong family history of autoimmune disease or maternal MMR or rubella immunisation shortly before, during or after pregnancy. This modified hypothesis could thereby explain the negative findings of the epidemiological studies. However, whatever the postulated induction interval or trends in incidence of autism, the present hypothesis 10 requires that the proportion of autistic children with regression and bowel symptoms be higher in cases given MMR vaccine before parents became concerned about their child's development and that the pattern of bowel problems and regression in autism should have changed after MMR was introduced.
We have investigated this possibility in a repeat survey in five of the original eight districts in North East Thames using the same methods as in the earlier study 5 but also collecting information on bowel problems and more details about regression. 11 In the repeat survey, 278 children with childhood autism and 195 with atypical autism were identified born between 1979 and 1998, a period which included the introduction of MMR vaccine to the UK (October 1988). The proportion of children with regression (25% overall) or bowel symptoms (17%) did not change significantly during this 20-year period. No significant differences were seen in rates of bowel problem, or regression in children who received the MMR vaccine before their parents became concerned about their development (where MMR might have caused, or triggered, the autism with regression or bowel problem), compared with those who received it only after such concern and those who had not received the MMR vaccine. Bowel problems identified were mainly constipation and associated diarrhoea. These are common in many children with learning difficulties, particularly those eating an unusual diet, which is a common feature of autism. Fombonne and Chakrabarti 12 found a very similar proportion of bowel problems-19% to our 17%-in a carefully validated group of children with autism in Stoke, UK. These findings suggest that underlying bowel disorder is an unlikely general feature in autism and no relationship between bowel problems in children with autism and MMR vaccination.
Our earlier survey 5 showed a rise in the recorded prevalence of autism by year of birth which peaked in 1992-3, then declined rapidly. The rise was thought to reflect in part better recording on computerised disability registers as well as other factors such as increased recognition, earlier diagnosis, wider acceptance of the diagnosis and changes in diagnostic criteria; the fall was thought to reflect delay in diagnosis in more recent cohorts-delay inherent to the condition. The repeat survey demonstrated a similar fall in the most recent cohorts. However from 1993 to 1997 there was a levelling off in the prevalence of autismat a rate for children age 5 to 14 years in this population, of some 2.6/1000 live births (core 1.5; atypical 1.1). This may prove to be the 'true' rate of severe autism in this population. There was no evidence of any effect which could be related to MMR vaccination.
These results provide no support for a 'new-variant' form of autism associated with bowel problems or regression and further evidence against any involvement of MMR vaccination in the initiation of autism. 
